BioXcel Therapeutics (BTAI) Registration Filing summary

Company overview and business model

• Focuses on developing transformative medicines in neuroscience and immuno-oncology using proprietary AI platforms to identify new therapeutic indications and accelerate drug development timelines.

• Lead neuroscience asset, BXCL501, is an orally dissolving film formulation of dexmedetomidine, approved as IGALMI for acute agitation in schizophrenia or bipolar disorder; commercialized since July 2022.

• Leverages existing approved drugs and big data to reduce development costs and address unmet medical needs.

Financial performance and metrics

• Recent public offering in November 2024 issued 5,600,000 shares and warrants at $0.48 per share, and pre-funded warrants for 9,000,000 shares at $0.479 per warrant.

• Audit opinion includes substantial doubt about ability to continue as a going concern as of December 31, 2023.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.

• Company bears registration and listing costs, while selling stockholders pay their own commissions and fees.